isatuximab   

GtoPdb Ligand ID: 8719

Synonyms: ch38SB19 | hu38SB19 | isatuximab-irfc | SAR-650984 | SAR650984 | Sarclisa®
isatuximab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Isatuximab is an anti-CD38 monoclonal antibody that was designed for anti-tumour potential [2].
A patent search identifies the peptide sequences of the light and heavy chain variable regions of isatuximab as SEQ ID NO: 22 and SEQ ID NO: 21 from patent US 8877899 B2 [6] (and equates to Ref mAB5 in the patent document). This patent further refers these sequences to WO2008047242 A8, but neither this or any associated patent (eg US20110262454 A1) provide peptide sequences to allow identification of isatuximab therein. The most likely patent defined embodiment being isatuximab is hu38SB19 [4].
Classification
Compound class Antibody
Approved drug? Yes (FDA (2020))
International Nonproprietary Names
INN number INN
10068 isatuximab
Synonyms
ch38SB19 | hu38SB19 | isatuximab-irfc | SAR-650984 | SAR650984 | Sarclisa®
Comments
Isatuximab is an anti-CD38 monoclonal antibody that was designed for anti-tumour potential [2].
A patent search identifies the peptide sequences of the light and heavy chain variable regions of isatuximab as SEQ ID NO: 22 and SEQ ID NO: 21 from patent US 8877899 B2 [6] (and equates to Ref mAB5 in the patent document). This patent further refers these sequences to WO2008047242 A8, but neither this or any associated patent (eg US20110262454 A1) provide peptide sequences to allow identification of isatuximab therein. The most likely patent defined embodiment being isatuximab is hu38SB19 [4].
Database Links
Specialist databases
IMGT/mAb-DB 539
Other databases
GtoPdb PubChem SID 252827377
Search PubMed clinical trials isatuximab
Search PubMed titles isatuximab
Search PubMed titles/abstracts isatuximab
SynPHARM 82660 (in complex with CD38)